Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11143492 | 0.95 | MEN1 (0.36) | MEN1KMT2AKDM4CWEE1L3MBTL1 | |
| SCHEMBL28851043 | 0.86 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL10576592 | 0.85 | MEN1 (0.38) | MEN1KMT2AKDM4CL3MBTL1GRM5 | |
| SCHEMBL5857211 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4CWEE1GRM5 | |
| SCHEMBL1921106 | 0.83 | MEN1 (0.34) | MEN1KMT2AKDM4CL3MBTL1GRM5 | |
| SCHEMBL7881560 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4CWEE1GRM5 | |
| SCHEMBL6151098 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4CWEE1GRM5 | |
| SCHEMBL10468432 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4CWEE1GRM5 | |
| SCHEMBL21641751 | 0.83 | MEN1 (0.36) | MEN1KMT2AKDM4CWEE1GRM5 | |
| SCHEMBL23014986 | 0.82 | MEN1 (0.35) | MEN1KMT2AWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114782-A1 | SMALL-MOLECULE MODULATORS OF SPIKE PROTEIN | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-1334095-B1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1334095-A4 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6693203-B2 | REACTING NOPINONE ENOLATE WITH ALKYL 7-HALO-5-HEPTYNOATE, REACTING PRODUCT WITH HYDROXYLAMINE, TREATING WITH TITANIUM TRICHLORIDE AND BORANE REAGENT, HYDROGENATING, REACTING WITH 5-HYDROXY-4-BENZOTHIOPHENECARBOXYLIC ACID, HYDROLYZING | SHIONOGI & CO., LTD (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | LARSEN ROBERT (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1334095-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032892-A1 | PROCESS FOR THE PREPARATION OF PGD2 ANTAGONIST | SHIONOGI & CO., LTD (JP) | 2002-04-25 | — | — | WO | disclosed |
| US-4672066-A | TREATMENT OF ALLERGIC CONDITIONS AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1987-06-09 | — | — | US | disclosed |
| US-4628115-A | LEUKOTRIENE ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1986-12-09 | — | — | US | disclosed |
| EP-0007180-B1 | PROSTAGLANDIN ANALOGUE TRIAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1983-03-30 | — | — | EP | disclosed |
| EP-0020039-A1 | Imidazole derivatives, their preparation and their pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1980-12-10 | — | — | EP | disclosed |
| EP-0007180-A1 | Prostaglandin analogue triazole derivatives, processes for their preparation and a pharmaceutical composition containing them | BEECHAM GROUP PLC (GB) | 1980-01-23 | — | — | EP | disclosed |
| US-4161608-A | 11 Hydroxy methyl 11-deoxyprostaglandin E1 | AYERST, MCKENNA AND HARRISON LIMITED (CA) | 1979-07-17 | — | — | US | disclosed |
| US-4100343-A | 11-Deoxyprostaglandin derivatives | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1978-07-11 | — | — | US | disclosed |
| US-4089898-A | 11-Deoxyprostaglandin derivatives | AYERST, MCKENNA & HARRISON LTD. (CA) | 1978-05-16 | — | — | US | disclosed |
| US-RE29587-E | PROSTAGLANDINS | ROUSSEL UCLAF (FR) | 1978-03-21 | — | — | US | disclosed |
| US-4054741-A | Derivatives of prostanoic acid | AYERST MCKENNA & HARRISON LTD. (CA) | 1977-10-18 | — | — | US | disclosed |
| US-4036856-A | PROSTAGLANDINS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-07-19 | — | — | US | disclosed |
| US-4024172-A | Preparation of prostanoic acid derivatives | ROUSSEL-UCLAF (FR) | 1977-05-17 | — | — | US | disclosed |
| US-4006136-A | Prostaglandin intermediates | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199702-A1 | Process for the preparation of pgd2 antagonist | PTGDR, PTGDR2, PTGER2 | MEN1 4673/4885KMT2A 2186/4885KDM4C 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.